初始直接喉镜检查与仅经口机器人手术治疗原发灶不明HPV阳性口咽鳞状细胞癌的比较
本研究为回顾性队列,纳入2014至2024年57例原发灶不明(cTx)HPV阳性口咽鳞状细胞癌患者,比较直接喉镜活检联合经口机器人手术(TORS)与仅TORS的围手术期结局、肿瘤识别及肿瘤学结局。两组围手术期病程与5年无病生存无差异;结论认为初始直接喉镜活检可能不必要地延迟 definitive 手术并增加医疗费用。
要点
- 57例中20例(35%)未行直接喉镜活检而直接TORS+颈清扫。
- 直接喉镜活检原发灶识别率38%,联合原发与二次TORS为74%。
- 仅19%的cTx患者最终病理仍为真原发不明(pT0)。
核心结论
- 对原发灶不明HPV阳性口咽鳞状细胞癌,初始直接喉镜活检与仅初始TORS的围手术期和肿瘤学结局相似,且可能不必要地延迟根治性手术并增加医疗费用。
研究设计与样本
- 回顾性队列,单机构三级转诊中心,纳入2014至2024年接受TORS的HPV阳性鳞状细胞癌原发灶不明(cTx)患者。
- 比较接受直接喉镜活检联合TORS与仅TORS的患者。
主要发现
- 57例患者体检、软式喉镜和PET/CT均无原发灶证据,其中20例(35%)未行直接喉镜活检而接受TORS+颈清扫。
- 直接喉镜活检原发灶识别率为38%,联合原发与二次TORS为74%。
- 所有cTx患者中仅19%最终病理仍为真原发不明(pT0)。
- 两组人口学与围手术期病程相似;TORS能识别大多数舌根病变(83%)。
- 两组总原发肿瘤大小(中位0.8 cm vs 1.0 cm)、淋巴结负荷、TNM分类、辅助治疗或5年无病生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to determine whether initial direct laryngoscopy with biopsy (DLBx) before transoral robotic surgery (TORS) has differences in perioperative outcomes, tumor identification, and oncologic outcomes for unknown primary oropharyngeal human papillomavirus (HPV+) squamous cell carcinoma (OPSCC). STUDY DESIGN: A retrospective cohort. SETTING: A single-institution, tertiary referral center. METHODS: All patients with HPV+ squamous cell carcinoma and unknown primary (cTx) undergoing TORS from 2014 to 2024 were collected. Patients receiving DLBx + TORS versus TORS alone were compared. RESULTS: A total of 57 patients had no evidence of primary disease on exam, flexible laryngoscopy, and PET/CT imaging, of which 20 (35%) underwent TORS + neck dissection without previous DLBx. Primary tumor was identified on 38% of DLBx and 74% of combined primary and secondary TORS. Only 19% of all cTx patients remained true unknown primary on final pathology (pT0). Demographics and perioperative courses were similar between the two groups. TORS was able to detect primary tumor in the majority of tongue base disease (83%). There were no differences in overall primary tumor size (median 0.8 vs. 1.0 cm), nodal burden, tumor, node, metastasis classification, adjuvant treatment, or 5-year disease-free survival. CONCLUSION: Initial DLBx for unknown primary HPV+ OPSCC has similar perioperative and oncologic outcomes to performing initial TORS alone and may unnecessarily delay definitive surgery and add healthcare costs. LEVEL OF EVIDENCE: IV.
引用
- Jones AJ, Robinson PZ, Xie DX, et al. Initial Direct Laryngoscopy Versus TORS Alone for Unknown Primary HPV+ Oropharyngeal Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2025. PMID: 40468647. doi:10.1002/ohn.1256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。